May 25, 2018
/
Featured Insights, Oncology
Nanotechnology in Drug Discovery and Design
This presentation takes the reader on an exciting journey, about the Science beneath the development of Oncology Nano Drug delivery systems. How the tumor mico and macro environments throws conspicuous challenges to the nanotech field? Furthermore, the presentation also gives a sneak view of Nanotherapeutics clinical landscape across development strategies and tumors.
Read More
May 14, 2018
/
Biosimilars, Featured Insights
Biosimilar Clinical Development – A Strategic Lever?
The presentation gives some key insights on the emerging biosimilars developer landscape with focus on US, EU, China, Japan, South Korea, MENA and Indian markets. Furthermore, it provides a detailed analysis on Clinical differentiation of players for major products (Bevacizumab, Trastuzumab, Adalimumab, Rituximab, Infliximab and etanercept).
Read More
February 12, 2018
/
Featured Insights, NOAC
Key Considerations When Developing a DOAC – Part 3
The currently approved direct oral anti-coagulants have proven to be safe and efficacious in prevention of stroke in patients with AF. However, the choice of DOAC is influenced by several factors including specific patient characteristics (renal function etc.), preference of OD versus BID, physicians comfort with the drug and the cost of drug to the patient.
Read More
December 21, 2017
/
Entrepreneurship, Featured Insights
Entrepreneurship Opportunities for Millennials in Pharma
Indian start-up ecosystem has been steadily growing with over 5200 start-ups in the country today. India has become the world’s...
Read More
August 10, 2017
/
Digital, Featured Insights
The Wearable Story – Part 1
The rapid consumer adoption of wearable devices for the collection of health data has inspired the next revolution in clinical trial operations. The integration of wearable health monitors with smartphones has opened up several fronts in clinical research. These integrated device-app-database systems can increase the frequency and accuracy of data collection, improve operational efficiencies, and achieve greater patient engagement in the clinical trial process.
Read More
August 10, 2017
/
Featured Insights, NOAC
Key Considerations When Developing a DOAC – Part 2
Direct oral anticoagulants were introduced in the market to simplify the anticoagulation treatment and eventually, replace warfarin. As previously discussed, these new agents have some advantages over warfarin. One of those advantage is that all DOACs are administered in fixed doses, only adjusted for specific factors like renal functions (in some cases). Since 2008, the US and EU regulatory bodies have approved several DOACs for specific indications based on their clinical trials demonstrating non-inferiority to warfarin. The availability of DOACs have changed the way stroke prevention in AF is managed.
Read MoreAugust 16, 2018
1L EGFRm+ Lung cancer is rapidly evolving and changing. Tagrisso is leading the pack with ORR of 77% and PFS of 18.9 mos. However, talking about overall survival, Dacomitinib is currently leading with OS of 34.1 mos. As Tagrioss’s final OS data is yet to be declared, the OS in […]
June 21, 2018
Pembrolizumab demonstrated durable anti-tumor activity in various tumors specially Hodgkin Lymphoma (ORR: 50%, mPFS: 12.2 months, 12 month PFS rate: 59.7%). The results indicate further study of pembrolizumab in pediatric patients with particulate interest in Lymphoma Phase 2 Study results confirms PR rate of 72% with that of phase 1 […]
June 5, 2018
Why is it so difficult to develop drugs for children with cancer? What can be done to stimlate investments in the pediatric oncology space? These questions are central to a new study published by MIT Sloan researchers that explores new business models for funding drug development to treat pediatric cancers. The […]
June 2, 2018
Research and development within the cancer field is continuously evolving and progressing. This video highlights the biggest milestones within the field of cancer research spanning 170 years —from the advent of general anesthesia opening the door for cancer surgery in the mid-1800s to the first gene therapy for cancer approved by the […]
June 2, 2018
Abstract 7504: Activity and tolerabilty of the first-in-class anti-CD47 antibody Hu5F9-G4 (5F9) with rituximab tolerated in relapsed/refractory non-Hodgkin lymphoma: Initial phase 1b/2 results. Conclusion: 5F9 + rituximab is a novel immunotherapy that inhibits a key macrophage/cancer checkpoint. It is well tolerated with no MTD reached and has promising clinical activity […]
June 2, 2018
Abstract 5003: Olaparib (Lynparza) combined with abiraterone (Zytiga) in patients with metastatic castration-resistant prostate cancer (mCRPC): a randomized phase II trial Conclusion: This is the first trial to show clinical benefit (increase in PFS) for mCRPC pts treated with a PARP inhibitor combined with abiraterone, regardless of HRRm status. Safety […]
June 2, 2018
Abstract 4011: A randomized phase II study of weekly paclitaxel ± trastuzumab in patients with HER2-positive advanced gastric or gastroesophageal junction cancer refractory to trastuzumab (Herceptin) combined with fluoropyrimidine and platinum: WJOG7112G. Conclusion: Continuation of trastuzumab beyond progression (TMB Strategy) in this patient population was not found to have the […]
June 2, 2018
Abstract 506: PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. Conclusion: Trastuzumab’s known side effects include a risk for heart problems. The women who had […]
April 26, 2018
Last week London had a pretty good weather, slightly chilly evenings and surprisingly, sun-kissed mornings! Yes, we were there to attend the 5th Biennial Biosimilars & Biobetters Congress in London (since the event was in London. I guess it’s a mandate to start with a weather update J) It was […]
- Date
- April 6, 2017
Related Post Non-Vitamin K Oral Anticoagulants Oncology Biosimilar Analysis Lucentis Biosimilars- Date
- March 30, 2017
Related Post Mesothelioma Competitor Landscape Oncology Biosimilar Analysis Lucentis Biosimilars- Date
- February 3, 2017
Related Post Mesothelioma Competitor Landscape Non-Vitamin K Oral Anticoagulants Oncology Biosimilar Analysis- Date
- January 9, 2017
Related Post Mesothelioma Competitor Landscape Non-Vitamin K Oral Anticoagulants Lucentis Biosimilars- Date
- December 17, 2016
Related Post Market Opportunity Assessment Market Entry Strategy Technology Landscape & Prioritization- Date
- December 17, 2016
Related Post CI Coverage for Novel Drug Delivery Technologies Market Entry Strategy Technology Landscape & Prioritization
